Analysis of adverse event of interstitial lung disease in men with prostate cancer receiving hormone therapy using the Food and Drug Administration Adverse Event Reporting System.
Bin WuPengfei ShenXi YinLei YuFengbo WuChen ChenJian LiTing XuPublished in: British journal of clinical pharmacology (2022)
Based on this FAERS pharmacovigilance analysis, the association between ILD events and hormone therapy drugs, including bicalutamide, flutamide, nilutamide, goserelin, degarelix and apalutamide, should not be ignored, especially in the Japanese population. Lung function of prostate cancer patients should be monitored when receiving the hormone therapy drugs mentioned above, especially for the first year post medication.
Keyphrases
- interstitial lung disease
- prostate cancer
- lung function
- adverse drug
- systemic sclerosis
- drug administration
- rheumatoid arthritis
- chronic obstructive pulmonary disease
- healthcare
- idiopathic pulmonary fibrosis
- radical prostatectomy
- stem cells
- drug induced
- risk assessment
- bone marrow
- smoking cessation
- replacement therapy